CBD combined with the blood pressure drug losartan synergistically inhibited inflammatory nitric oxide release by 80% in brain glial cells, compared to only 22-26% for either drug alone.
Read this if you are interested in CBD's anti-inflammatory potential and how drug combinations could enhance it.
80% synergisticCBD + losartan synergistically inhibited glial nitric oxide release vs 22-26% for either alone
What the researchers found
In LPS-stimulated glial cells, telmisartan and CBD alone reduced nitric oxide by 60% and 36% respectively. Together, they achieved 95% inhibition (additive effect). More strikingly, losartan (5µM) and CBD (5µM) synergistically inhibited nitric oxide release by 80%, far exceeding either alone (22% and 26%). CBD combined with dimethyl fumarate's metabolite MMF also showed synergistic effects (77% inhibition vs 35% and 12% alone). Both combinations also modulated inflammatory cytokines TNFα, IL-17, and interferon-γ.
Why it matters
Neuroinflammation drives many brain diseases. This study suggests that commonly prescribed blood pressure medications could dramatically enhance CBD's anti-inflammatory effects, opening possibilities for combination therapies for neurological conditions.
The numbers in context
- Telmisartan alone: 60% NO reduction; CBD alone: 36%
- Telmisartan + CBD: 95% NO inhibition (additive)
- Losartan (5µM) + CBD (5µM): 80% NO inhibition (synergistic)
- MMF + CBD: 77% NO inhibition (synergistic vs 35% + 12% alone)
- CBD + telmisartan: attenuated LPS-induced TNFα
- CBD ± telmisartan: 75% reduction in IL-17
How the study worked
In vitro study using LPS-stimulated glial cells. Measured nitric oxide release, TNFα, IL-17, and interferon-γ. Tested CBD alone and in combination with angiotensin receptor blockers (telmisartan, losartan) and dimethyl fumarate/monomethyl fumarate.
Who was studied
In vitro glial cell inflammation model
What this study cannot tell us
In vitro glial cell model only. Drug concentrations may not reflect achievable brain levels in vivo. LPS stimulation is an artificial inflammation model. Clinical relevance requires animal and human studies.
How to read the evidence
In vitro pharmacological study. Demonstrates clear synergy but requires in vivo and clinical validation.
When this study was published
Published in 2023. Represents emerging interest in CBD drug combination therapies.
The bigger picture
Drug repurposing and combination therapy are efficient paths to new treatments. The finding that common blood pressure medications synergize with CBD against neuroinflammation could accelerate clinical development since both drugs have established safety profiles.
Questions still open
- Would these synergistic effects occur in the brain of living animals?
- Could patients already taking ARBs for blood pressure benefit from adding CBD for neuroinflammation?
- What is the optimal CBD:ARB ratio for maximum anti-inflammatory effect?
Read the original research
An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release.
International journal of molecular sciences, 24(22)
Citation
Fleisher-Berkovich, Sigal; Battaglia, Veronica; Baratta, Francesca; Brusa, Paola; Ventura, Yvonne; Sharon, Nitzan; Dahan, Arik; Collino, Massimo; Ben-Shabat, Shimon. (2023). An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release.. International journal of molecular sciences, 24(22). https://doi.org/10.3390/ijms242216254